Antibodies and Fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
US11136377B2 · kind B2 · utility
0Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 2019 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | Sep 16, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain embodiments, this present invention provides antibodies and Fc fusion proteins with enhanced pharmacokinetics, such as biotinylated antibodies or biotinylated Fc fusion polypeptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.